Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Krispy Kreme Inc (DNUT) vs Eli Lilly And Co (LLY) Price & Performance

Krispy Kreme IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Krispy Kreme Inc vs Eli Lilly And Co — how do they compare? Krispy Kreme Inc trades at $3.14 (market cap $537.85M), while Eli Lilly And Co trades at $1,217.59 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2008× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals.

DNUTLLY
Market Cap
$537.85M$1.08T
Sector
Consumer StaplesHealth
52-Week High
$4.70$1.24K
52-Week Low
$2.92$639.43
Enterprise Value
$1.78B$1.13T
Dividend Yield
3.47%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Krispy Kreme Inc

Krispy Kreme (DNUT) trades at $3.14, down 5.99% with bearish technical signals. The company shows mixed fundamentals with a high P/E ratio of 216.5 but attractive P/S of 0.36 and P/B of 0.87. Recent Q2 2026 earnings showed a narrowed loss of $0.03 per share, beating expectations, while revenue declined 12.8% due to refranchising. CEO Josh Charlesworth emphasized turnaround progress with margin improvement and deleveraging (Bloomberg, August 6, 2026).

The outlook remains challenging with negative net income margins and ROE, though analyst sentiment is cautiously optimistic with 50% buy ratings. Key risks include execution of the turnaround strategy and competitive pressures. The stock presents a speculative opportunity if management can sustain operational improvements and return to profitability.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Krispy Kreme Inc

Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line

Read more on DNUT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY